On Nov 19, the program of Jiangsu Hailang Co., Ltd., with a total investment of 5 billion RMB by Yangtze River Pharmaceutical Group, was launched in Changzhou National Hi-Tech District (CND). Ding Chun, mayor of Changzhou, and Zhou Bin, secretary of the CPC Working Committee of CND, attended the groundbreaking ceremony.
Yangtze River Pharm has maintained good cooperation with CND since 2001 when the group established Zilong Pharmaceutical Co., Ltd. here in Changzhou. The company’s workshops producing small volume injections and freeze-dried powder injections have been authenticated by the new version of GMP 2015. The newly launched program will robustly drive CND’s development of new medicine and medical device industries.
Jiangsu Hailang Co., Ltd. is located in the Health Industrial Park, mainly involved in the R&D, manufacturing and sales of anti-tumor medicines, suspensions, oral solution, solid preparations, medical equipment and other products. After the design capacity is achieved, the annual sales volume is expected to exceed 10 billion RMB.
Up to now, CND has gathered more than 120 biomedicine and related enterprises which are mostly located in the Health Industrial Park. Among them, 15 enterprises each has reached output value of 100 million RMB. A number of well-known enterprises like Qianhong Biochemical and Fangyuan Pharmacy are playing a leading role in the productions of enzymes and polysaccharides medicines in China.
掃一掃在手機(jī)打開當(dāng)前頁  |
